QRM Process

Pharmaceutical Manufacturing: Is It the Antithesis of Creative Destruction?

PAT and QbD can only move forward if the industry sheds its habit of QbA (i.e., quality by analysis)

By Girish Malhotra, PE, President, EPCOT International, Inc.

If you are not automatically redirected, follow this link:


Free Subscriptions

Pharma Manufacturing Digital Edition

Access the entire print issue on-line and be notified each month via e-mail when your new issue is ready for you. Subscribe Today.

pharmamanufacturing.com E-Newsletters

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.